RoozGozinModerna's mRNA vaccine nearly halves the risk of resistant melanoma recurrence
Phase 3 study shows Moderna's mRNA vaccine reduces the risk of resistant melanoma returning.
Importance: 85 of 100
A study published in Nature shows that Moderna's mRNA vaccine can reduce the risk of recurrence of treatment-resistant melanoma by nearly half. These results come from a phase 3 trial. No further details about the mechanism of action or duration of effectiveness have been reported.